Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

Trial Details

NCT ID

NCT03934372

Phase

PHASE1 / PHASE2

Sponsor

Incyte Biosciences International Sàrl

Status

RECRUITING

Cancer Type

Acute Lymphoblastic (ALL) Leukemia

Interventions

• Ponatinib

Locations (sample)

• Ghent, Belgium|51.05,3.71667
• Paris, France|48.85341,2.3488
• Paris, France|48.85341,2.3488
• Poitiers, France|46.58261,0.34348
• Rennes, France|48.11109,-1.67431

Key Eligibility Criteria

• Histologically or cytologically confirmed diagnosis of the following malignancies:
• \- Phase 1: CP-CML, BP-CML, AP-CML ALL. AML. Other leukemias. Lymphoma. Any other tumors, including tumors of the CNS, for which standard therapy i…
• \- Phase 2, Group A with CP-CML: CP-CML at the time of study entry and must be resistant to or intolerant of at least 1 prior BCR-ABL-targeted TKI …
• Must have 1 bone marrow aspirate with documentation of BCR-ABL translocation by conventional cytogenetics, metaphase FISH, or q-PCR performed withi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.